WGU D116 Advanced Pharmacology OA
& Actual Exam 2026/2027 | WGU D116
Advanced Pharm | Verified Q&A | Pass
Guaranteed - A+ Graded
Section 1: Pharmacokinetics & Pharmacodynamics (Questions 1-12)
Q1: A patient has been taking rifampin (a strong CYP450 inducer) for tuberculosis. The APRN prescribes
warfarin for a new diagnosis of atrial fibrillation. What effect would the APRN anticipate?
A. Increased INR and higher bleeding risk
B. Decreased INR and lower anticoagulant effect
C. No change in warfarin metabolism
D. Immediate warfarin resistance requiring triple the dose
Correct Answer: B
Rationale: Rifampin induces CYP450 enzymes, accelerating warfarin metabolism and reducing its
anticoagulant effect, requiring a higher warfarin dose to achieve therapeutic INR.
Q2: A drug with a high first-pass effect is administered orally. Which pharmacokinetic principle best
explains why the prescribed dose is significantly higher than the intravenous dose?
A. Decreased volume of distribution
B. Reduced systemic bioavailability due to presystemic hepatic metabolism
C. Increased renal elimination of the active metabolite
D. Enhanced protein binding in the gastrointestinal tract
Correct Answer: B
,Rationale: The first-pass effect refers to the significant metabolism of a drug in the liver before it
reaches systemic circulation, drastically reducing its oral bioavailability compared to IV administration.
Q3: A patient with severe liver cirrhosis is prescribed a highly protein-bound drug (98%). What is the
primary pharmacokinetic concern in this patient?
A. Decreased renal clearance of the free drug
B. Increased risk of toxicity due to higher levels of free (unbound) drug
C. Accelerated metabolism due to hepatic enzyme induction
D. Prolonged half-life due to increased albumin production
Correct Answer: B
Rationale: Cirrhosis leads to hypoalbuminemia, reducing the number of protein-binding sites and
increasing the fraction of free, pharmacologically active drug, which elevates the risk of toxicity.
Q4: An APRN is calculating when a medication will reach steady state. The drug has a half-life of 24
hours. Approximately how long will it take to reach steady-state concentration?
A. 24 hours
B. 48 hours
C. 5 days
D. 10 days
Correct Answer: C
Rationale: It takes approximately four to five half-lives for a drug to reach steady state; therefore, a drug
with a 24-hour half-life will reach steady state in about 5 days (120 hours).
Q5: Which of the following scenarios best describes a drug acting as a partial agonist?
A. A drug that binds to a receptor and produces the maximum possible response
B. A drug that binds to a receptor, produces a submaximal response, and blocks other agonists from
binding
C. A drug that binds to a receptor and prevents all endogenous and exogenous agonists from acting
, D. A drug that binds to an allosteric site to enhance the effect of an endogenous agonist
Correct Answer: B
Rationale: Partial agonists bind to the same receptor site as full agonists but produce a submaximal
response even at full receptor occupancy, while simultaneously blocking full agonists from binding.
Q6: A patient is taking a medication with a narrow therapeutic index. What is the most critical
prescribing consideration for the APRN?
A. The drug can be dosed empirically without laboratory monitoring
B. Small changes in drug concentration can lead to therapeutic failure or severe toxicity
C. The drug has a wide margin of safety between the effective dose and lethal dose
D. The drug is primarily metabolized by renal excretion rather than hepatic enzymes
Correct Answer: B
Rationale: A narrow therapeutic index means the difference between a therapeutic and toxic dose is
very small, necessitating precise dosing and often routine therapeutic drug monitoring.
Q7: A patient taking grapefruit juice daily is started on amlodipine. What pharmacokinetic interaction is
expected?
A. Decreased bioavailability of amlodipine due to intestinal CYP3A4 induction
B. Increased bioavailability of amlodipine due to inhibition of intestinal CYP3A4
C. Accelerated renal clearance of amlodipine
D. Increased protein binding of amlodipine
Correct Answer: B
Rationale: Grapefruit juice irreversibly inhibits intestinal CYP3A4 enzymes, reducing the presystemic
metabolism of amlodipine and increasing its systemic bioavailability.
Q8: A patient with chronic kidney disease is prescribed a water-soluble drug. How will the
pharmacokinetics of this drug be primarily affected?
A. Increased first-pass metabolism
& Actual Exam 2026/2027 | WGU D116
Advanced Pharm | Verified Q&A | Pass
Guaranteed - A+ Graded
Section 1: Pharmacokinetics & Pharmacodynamics (Questions 1-12)
Q1: A patient has been taking rifampin (a strong CYP450 inducer) for tuberculosis. The APRN prescribes
warfarin for a new diagnosis of atrial fibrillation. What effect would the APRN anticipate?
A. Increased INR and higher bleeding risk
B. Decreased INR and lower anticoagulant effect
C. No change in warfarin metabolism
D. Immediate warfarin resistance requiring triple the dose
Correct Answer: B
Rationale: Rifampin induces CYP450 enzymes, accelerating warfarin metabolism and reducing its
anticoagulant effect, requiring a higher warfarin dose to achieve therapeutic INR.
Q2: A drug with a high first-pass effect is administered orally. Which pharmacokinetic principle best
explains why the prescribed dose is significantly higher than the intravenous dose?
A. Decreased volume of distribution
B. Reduced systemic bioavailability due to presystemic hepatic metabolism
C. Increased renal elimination of the active metabolite
D. Enhanced protein binding in the gastrointestinal tract
Correct Answer: B
,Rationale: The first-pass effect refers to the significant metabolism of a drug in the liver before it
reaches systemic circulation, drastically reducing its oral bioavailability compared to IV administration.
Q3: A patient with severe liver cirrhosis is prescribed a highly protein-bound drug (98%). What is the
primary pharmacokinetic concern in this patient?
A. Decreased renal clearance of the free drug
B. Increased risk of toxicity due to higher levels of free (unbound) drug
C. Accelerated metabolism due to hepatic enzyme induction
D. Prolonged half-life due to increased albumin production
Correct Answer: B
Rationale: Cirrhosis leads to hypoalbuminemia, reducing the number of protein-binding sites and
increasing the fraction of free, pharmacologically active drug, which elevates the risk of toxicity.
Q4: An APRN is calculating when a medication will reach steady state. The drug has a half-life of 24
hours. Approximately how long will it take to reach steady-state concentration?
A. 24 hours
B. 48 hours
C. 5 days
D. 10 days
Correct Answer: C
Rationale: It takes approximately four to five half-lives for a drug to reach steady state; therefore, a drug
with a 24-hour half-life will reach steady state in about 5 days (120 hours).
Q5: Which of the following scenarios best describes a drug acting as a partial agonist?
A. A drug that binds to a receptor and produces the maximum possible response
B. A drug that binds to a receptor, produces a submaximal response, and blocks other agonists from
binding
C. A drug that binds to a receptor and prevents all endogenous and exogenous agonists from acting
, D. A drug that binds to an allosteric site to enhance the effect of an endogenous agonist
Correct Answer: B
Rationale: Partial agonists bind to the same receptor site as full agonists but produce a submaximal
response even at full receptor occupancy, while simultaneously blocking full agonists from binding.
Q6: A patient is taking a medication with a narrow therapeutic index. What is the most critical
prescribing consideration for the APRN?
A. The drug can be dosed empirically without laboratory monitoring
B. Small changes in drug concentration can lead to therapeutic failure or severe toxicity
C. The drug has a wide margin of safety between the effective dose and lethal dose
D. The drug is primarily metabolized by renal excretion rather than hepatic enzymes
Correct Answer: B
Rationale: A narrow therapeutic index means the difference between a therapeutic and toxic dose is
very small, necessitating precise dosing and often routine therapeutic drug monitoring.
Q7: A patient taking grapefruit juice daily is started on amlodipine. What pharmacokinetic interaction is
expected?
A. Decreased bioavailability of amlodipine due to intestinal CYP3A4 induction
B. Increased bioavailability of amlodipine due to inhibition of intestinal CYP3A4
C. Accelerated renal clearance of amlodipine
D. Increased protein binding of amlodipine
Correct Answer: B
Rationale: Grapefruit juice irreversibly inhibits intestinal CYP3A4 enzymes, reducing the presystemic
metabolism of amlodipine and increasing its systemic bioavailability.
Q8: A patient with chronic kidney disease is prescribed a water-soluble drug. How will the
pharmacokinetics of this drug be primarily affected?
A. Increased first-pass metabolism
